The current status of immunotherapies in esophagogastric cancer Review
| Author: | Ku, G. Y. |
| Review Title: | The current status of immunotherapies in esophagogastric cancer |
| Abstract: | This review summarizes completed and ongoing studies evaluating the activity of immune checkpoint inhibitors in esophagogastric cancer. © 2018 Elsevier Inc. |
| Keywords: | signal transduction; cancer chemotherapy; cancer survival; unclassified drug; review; squamous cell carcinoma; drug efficacy; drug safety; risk benefit analysis; drug approval; outcome assessment; protein function; adenocarcinoma; cytotoxic t lymphocyte antigen 4 antibody; ipilimumab; ticilimumab; cancer immunotherapy; immune system; immune response; immunotherapy; stomach cancer; immunity; cytotoxic t lymphocyte antigen 4; autoantibody; homeostasis; esophagus cancer; t lymphocyte activation; esophageal; pd-1; programmed death 1 ligand 1; programmed death 1 receptor; pd-l1; gastric; esophagogastric cancer; programmed death ligand 1 antibody; programmed death 1 antibody; bacterial toxin; nivolumab; immune checkpoint; human; priority journal; pembrolizumab; durvalumab; atezolizumab; avelumab; coley toxin |
| Journal Title: | Hematology/Oncology Clinics of North America |
| Volume: | 33 |
| Issue: | 2 |
| ISSN: | 0889-8588 |
| Publisher: | Elsevier Inc. |
| Date Published: | 2019-04-01 |
| Start Page: | 323 |
| End Page: | 338 |
| Language: | English |
| DOI: | 10.1016/j.hoc.2018.12.007 |
| PUBMED: | 30833003 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | Review -- Export Date: 1 April 2019 -- Source: Scopus |
